Catalent (CTLT) 10-Q3 Nov 202021 Q1 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Oct. 29, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-36587
Entity Registrant Name	Catalent, Inc.
Entity Incorporation, State or Country Code	DE
Entity Address, State or Province	NJ
Entity Tax Identification Number	20-8737688
Entity Address, Address Line One	14 Schoolhouse Road,
Entity Address, City or Town	Somerset,
Entity Address, Postal Zip Code	08873
City Area Code	(732)
Local Phone Number	537-6200
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock
Trading Symbol	CTLT
Security Exchange Name	NYSE
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001596783
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding (shares)		164,697,598

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Net revenue	$ 845.7	$ 664.7
Cost of sales	596.8	487
Gross margin	248.9	177.7
Selling, general, and administrative expenses	164.7	142.8
Impairment charges and (gain)/loss on sale of assets	1.8	(0.2)
Restructuring and other	0.9	0.7
Operating earnings	81.5	34.4
Interest expense, net	25.3	36.3
Other (income)/expense, net	(11.2)	4.9
Earnings from continuing operations, before income taxes	67.4	(6.8)
Income tax expense	(15)	(6.9)
Net earnings/(loss)	82.4	0.1
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic	13.6	8.1
Net Income (Loss) Available to Common Stockholders, Basic	$ 68.8	$ (8)
Earnings Per Share, Basic	$ 0.42	$ (0.05)
Earnings Per Share, Diluted	$ 0.41	$ (0.05)

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income / (Loss) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Other comprehensive income/(loss), net of tax
Net earnings/(loss)	$ 82.4	$ 0.1
Foreign currency translation adjustments	15.9	(21.8)
Pension and other post-retirement adjustments	0.5	(0.3)
Net change in derivatives and hedges, net of tax	(0.1)	0
Other comprehensive income/(loss), net of tax	16.3	(22.1)
Comprehensive income/(loss)	$ 98.7	$ (22)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2020	Jun. 30, 2020
Current assets:
Cash and cash equivalents	$ 1,007	$ 953.2
Trade receivables, net	700.9	838.1
Inventories	384.3	323.8
Prepaid expenses and other	263.9	177.9
Total current assets	2,356.1	2,293
Property, plant, and equipment, net	2,035.5	1,900.8
Other assets:
Goodwill	2,490.4	2,470.6
Other intangibles, net	870.3	888.7
Deferred Income Tax Assets, Net	57.1	49.4
Other Assets, Noncurrent	174.8	174
Total assets	7,984.2	7,776.5
Current Liabilities:
Debt, Current	73.4	72.9
Accounts payable	329.4	321
Other accrued liabilities	516.9	499.3
Total current liabilities	919.7	893.2
Long-term obligations, less current portion	2,985.3	2,945.1
Pension liability	135.5	135.2
Deferred Income Taxes	83.6	94
Other liabilities	181.4	203.6
Commitments and Contingencies (see Note 15)	0	0
Total liabilities	4,305.5	4,271.1
Temporary Equity, Carrying Amount, Attributable to Parent	606.6	606.6
Common Stock, Value, Outstanding	1.6	1.6
Preferred Stock, Value, Outstanding	0	0
Additional paid in capital	3,901.4	3,818.7
Accumulated deficit	(460.9)	(535.2)
Accumulated other comprehensive income/(loss)	(370)	(386.3)
Total shareholders' equity	3,072.1	2,898.8
Total liabilities, redeemable preferred stock, and shareholders’ equity	$ 7,984.2	$ 7,776.5

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Jun. 30, 2020
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common stock, shares issued (shares)	164,567,095	162,788,043
Common Stock, Shares, Outstanding	164,567,095	162,788,043
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	650,000	650,000
Preferred Stock, Shares Outstanding	650,000	650,000

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholder's Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income/(Loss)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common Stock, Shares, Outstanding		145,738,300
Beginning Balance at Jun. 30, 2019	$ 1,681.6	$ 1.5	$ 2,757.4	$ (723.4)	$ (353.9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Value, Stock Options Exercised	0	0
Stock-based compensation	16.6		16.6
Cash paid, in lieu of equity, for tax withholding	(18.1)		(18.1)
Non-qualified stock			0.7
Dividends, Preferred Stock	8.1			8.1
Net earnings/(loss)	0.1			0.1
Other comprehensive income/(loss), net of tax	(22.1)				(22.1)
Ending Balance at Sep. 30, 2019	$ 1,649.3	$ 1.5	2,755.2	(731.4)	(376)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share issuances related to stock-based compensation		497,400
Common Stock, Shares, Outstanding		146,235,700
Common Stock, Shares, Outstanding	162,788,043	162,788,000
Beginning Balance at Jun. 30, 2020	$ 2,898.8	$ 1.6	3,818.7	(535.2)	(386.3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity offering, sale of common stock,	81.8	0	81.8
Stock Issued During Period, Value, Stock Options Exercised	0	0
Stock-based compensation	18.7		18.7
Cash paid, in lieu of equity, for tax withholding	(19.6)		(19.6)
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	1.8		1.8
Non-qualified stock	(0.7)
Dividends, Preferred Stock	8.1			8.1
Net earnings/(loss)	82.4			82.4
Other comprehensive income/(loss), net of tax	16.3				16.3
Ending Balance at Sep. 30, 2020	3,072.1	$ 1.6	3,901.4	$ (460.9)	$ (370)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity offering, sale of common stock		1,162,500
Share issuances related to stock-based compensation		616,600
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	$ 1.8		$ 1.8
Common Stock, Shares, Outstanding	164,567,095	164,567,100

Consolidated Statement of Cha_2

Consolidated Statement of Changes in Shareholder's Equity Consolidated Statement of Changes in Shareholders' Equity (Parenthetical) - shares	Jun. 15, 2020	Feb. 06, 2020	Sep. 30, 2020	Sep. 30, 2019
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance - Common Stock Outstanding (shares)			162,788,043
Equity offering, sale of common stock	7,700,000	8,400,000
Ending Balance - Common Stock Outstanding (shares)			164,567,095
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance - Common Stock Outstanding (shares)			162,788,000	145,738,300
Equity offering, sale of common stock			1,162,500
Share issuances related to stock-based compensation			616,600	497,400
Ending Balance - Common Stock Outstanding (shares)			164,567,100	146,235,700

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings/(loss)	$ 82.4	$ 0.1
Adjustments to reconcile earnings/(loss) from operations to net cash from operations:
Depreciation and amortization	69.1	60.6
Non-cash foreign currency transaction (gain)/loss, net	(3.8)	(0.1)
Amortization and write-off of debt financing costs	1.7	1.5
Asset impairments charges and (gain)/loss on sale of assets	1.8	(0.2)
Derivative, Gain (Loss) on Derivative, Net	9	(8.9)
Stock-based compensation	18.7	16.6
Provision/(benefit) for deferred income taxes	(10.6)	(0.6)
Provision for bad debts and inventory	7.9	4.1
Change in operating assets and liabilities:
Decrease/(increase) in trade receivables	143.7	34.1
Decrease/(increase) in inventories	(65.4)	0.2
Increase/(decrease) in accounts payable	6.6	(47.3)
Other assets/accrued liabilities, net — current and non-current	(93.4)	(52.7)
Net Cash Provided by (Used in) Operating Activities, Total	149.7	25.2
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment and other productive assets	(149.6)	(73.5)
Payment for acquisitions, net of cash acquired	0	(10.7)
Payments to Acquire Investments	1.6	0.7
Net cash (used in) investing activities	(151.2)	(84.9)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net change in other borrowings	(3.9)	(2.5)
Payments related to long-term obligations	(2.4)	(3.3)
Dividends and Interest Paid	8.1	11.9
Proceeds from sale of common stock, net	83.6	0
Cash paid, in lieu of equity, for tax withholding	(19.6)	(18.1)
Net cash (used in)/provided by financing activities	49.6	(35.8)
Effect of foreign currency exchange on cash	5.7	(6.5)
NET INCREASE/(DECREASE) IN CASH AND EQUIVALENTS	53.8	(102)
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD	953.2	345.4
CASH AND EQUIVALENTS AT END OF PERIOD	1,007	243.4
SUPPLEMENTARY CASH FLOW INFORMATION:
Interest paid	43.4	24.8
Income taxes paid, net	$ 8.8	$ 12.7

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Catalent, Inc. ( “ Catalent ” or the “ Company ” ) directly and wholly owns PTS Intermediate Holdings LLC ( “ Intermediate Holdings ” ). Intermediate Holdings directly and wholly owns Catalent Pharma Solutions, Inc. ( “ Operating Company ” ). The financial results of Catalent are comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ( “U.S. GAAP ” ) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending June 30, 2021. The consolidated balance sheet at June 30, 2020 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information on the Company's accounting policies and footnotes, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2020 filed with the Securities and Exchange Commission (the “ SEC ” ). Foreign Currency Translation The financial statements of the Company’s operations are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of operations outside the U.S. into U.S. dollars are accumulated as a component of other comprehensive income/(loss) utilizing period-end exchange rates. Since July 1, 2018, the Company has accounted for its Argentine operations as highly inflationary. Research and Development Costs The Company expenses research and development costs as incurred. Research and development costs amounted to $6.4 million and $4.6 million for the three months ended September 30, 2020 and 2019, respectively. Recent Financial Accounting Standards Recently Adopted Accounting Standards In August 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted the guidance on July 1, 2020. The guidance did not have a material impact on the Company’s financial condition or results of operations. In August 2018, the FASB issued ASU 2018-13 , Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirement for Fair Value Measurement , which changes the disclosure requirements on fair value measurements in Accounting Standards Codification ( “ ASC ”) 820 Fair Value Measurement . The guidance eliminates certain disclosure requirements that are no longer considered cost beneficial and adds new disclosure requirements for Level 3 fair value measurements. The Company adopted the guidance on July 1, 2020. The guidance did not have a material impact on the Company’s financial condition or results of operations. In June 2016, the FASB issued ASU 2016-13 , Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which introduces a new accounting model known as Credit Expected Credit Losses ( “ CECL ” ). CECL requires earlier recognition of credit losses on financial assets, while also providing additional transparency about credit risk. The CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses for financial assets at the time they are originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. This model replaces the multiple existing impairment models in current U.S. GAAP, which generally require that a loss be incurred before it is recognized. The new standard applies to receivables arising from revenue transactions such as contract assets and accounts receivables. The Company adopted the amended guidance using a modified retrospective approach on July 1, 2020. The amended guidance did not have a material impact on the Company’s financial condition or results of operations. New Accounting Standards Not Adopted as of September 30, 2020 In March 2020, the FASB issued ASU 2020-04 , Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional guidance to ease the potential burden in accounting for the discontinuation of a reference rate such as LIBOR, formerly known as the London Interbank Offered Rate, because of reference rate reform. The expedients and exceptions provided by the guidance do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. The ASU is effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12 , Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which eliminates certain exceptions related to the incremental approach for intra-period allocation, deferred tax recognition requirement for changes in equity method investments and foreign subsidiaries, and methodology for calculating income taxes in an interim period. The guidance also simplifies certain aspects of the accounting for franchise taxes, the accounting for step-up in the tax basis of goodwill, and accounting for the change in the enacted change in tax laws or rates. The ASU will be effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.

Revenue Recognition

Revenue Recognition	3 Months Ended
Revenue Recognition	Sep. 30, 2020
Revenue Recognition [Abstract]
Revenue from Contract with Customer [Policy Text Block]	REVENUE RECOGNITION The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers . The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. The Company measures the revenue from customers based on the consideration specified in its contracts, excluding any sales incentive or amount collected on behalf of a third party. The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material. The following tables allocate revenue, for the three months ended September 30, 2020 and September 30, 2019, by type of activity and reporting segment (in millions): Three Months Ended September 30, 2020 Biologics Softgel & Oral Technologies Oral & Specialty Delivery Clinical Supply Services Total Manufacturing & commercial product supply $ 89.9 $ 190.6 $ 103.5 $ — $ 384.0 Development services 287.2 30.5 54.8 — 372.5 Clinical supply services — — — 92.7 92.7 Total $ 377.1 $ 221.1 $ 158.3 $ 92.7 $ 849.2 Inter-segment revenue elimination (3.5) Combined net revenue $ 845.7 Three Months Ended September 30, 2019 Biologics Softgel & Oral Technologies Oral & Specialty Delivery Clinical Supply Services Total Manufacturing & commercial product supply $ 64.4 $ 242.0 $ 76.0 $ — $ 382.4 Development services 124.2 21.7 56.6 — 202.5 Clinical supply services — — — 84.6 84.6 Total $ 188.6 $ 263.7 $ 132.6 $ 84.6 $ 669.5 Inter-segment revenue elimination (4.8) Combined net revenue $ 664.7 The following table allocates revenue by the location where the goods were made or the service performed: Three Months Ended (Dollars in millions) 2020 2019 United States $ 516.9 $ 362.3 Europe 281.4 210.1 International Other 68.8 110.9 Elimination of revenue attributable to multiple locations (21.4) (18.6) Total $ 845.7 $ 664.7 Contract Liabilities Contract liabilities relate to cash consideration that the Company receives in advance of satisfying the related performance obligations. The contract liabilities balance as of September 30, 2020 and June 30, 2020 are as follows: (Dollars in millions) Balance at June 30, 2020 $ 218.4 Balance at September 30, 2020 $ 243.9 Revenue recognized in the period from July 1 through September 30, 2020: Amounts included in contract liability at the beginning of the period $ 48.2 Contract Assets C ontract assets primarily relate to the Company's conditional right to receive consideration for services that have been performed for the customer as of September 30, 2020 relating to its development services but had not yet been invoiced as of September 30, 2020. Contract assets are transferred to trade receivables, net when the Company’s right to receive the consideration becomes unconditional. Contract assets totaled $116.2 million and $61.4 million as of September 30, 2020 and June 30, 2020, respectively. Contract assets are included in Prepaid expenses and other as they are expected to be transferred to trade receivables within 12 months of September 30, 2020. Receivables and Allowance for Doubtful Accounts

Business Combinations

Business Combinations	3 Months Ended
Business Combinations	Sep. 30, 2020
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	BUSINESS COMBINATIONS Novavax Transaction In July 2019, the Company acquired from Novavax Inc. (“Novavax”) certain property, plant and equipment, rights to two facilities under leases in southern Maryland, certain raw material inventory, and the right to assume the employment of more than 100 Novavax employees located a t those facilities in the areas of operations, quality, and product development, among other things. The Company made a cash payment of $18.3 million in connection with the acquisition. The Company considers the transaction to be a business combination under ASC 805, Business Combinations and accounted for it using the acquisition method of accounting. The Company estimated fair values at the acquisition date for the allocation of consideration to the acquired items. The aggregate purchase consideration was funded with cash on hand. As a result of the fair value allocations, the Company recognized property, plant, and equipment of $15.6 million and $0.3 million for inventory. The remainder of the fair value, $2.4 million, was preliminarily allocated to goodwill, primarily the value of the existing organized and trained work force. During the measurement period that ended in July 2020, the Company finalized the fair values of the net assets acquired, which was not materially different from the preliminary estimates. The Novavax transaction expanded the Company’s gene therapy early-development capabilities and supplemented its pool of experienced biologics operatives to support growth in its Biologics segment. Anagni Acquisition In January 2020, the Company acquired an oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy (“Anagni”) from a unit of Bristol-Myers Squibb Company (“BMS”). The Company paid to BMS $55.3 million in cash as part of the purchase consideration and as consideration for the provision of certain services to facilitate the transition from BMS to Company ownership. At the closing of this acquisition, BMS also entered into a five-year agreement for continuing supply by the Company of certain products formerly produced by BMS at the Anagni facility. Due to the variety of activities performed at Anagni, the results of the Anagni facility are allocated between the Oral and Specialty Delivery and Biologics segments. The total cash consideration was allocated between the facility purchase and the transitional services arrangement, with $52.2 million assigned to the purchase consideration and the balance to transitional services. The Company funded the entire amount with cash on hand and has preliminarily allocated the purchase price among the acquired assets, recognizing property, plant, and equipment of $34.2 million, inventory of $6.5 million, and prepaid expenses and other of $12.2 million. The remainder of the value was allocated to deferred tax assets and certain employee-related liabilities assumed in the acquisition. The Company expects to finalize its allocation over the next several months, but, in any event, within one year from the closing. Masthercell Global Inc. Acquisition In February 2020, the Company acquired 100% of the equity interest in Masthercell Global Inc. (“MaSTherCell”) for an aggregate purchase price of $323.3 million, subject to adjustment, which was funded with the net proceeds of the Company’s February 2020 public offering (the “February 2020 Equity Offering”) of its common stock, par value $0.01 (“Common Stock”). See Note 13, Equity and Accumulated Other Comprehensive Income/(Loss) . MaSTherCell is a contract development and manufacturing organization focused on the development and manufacture of autologous and allogeneic cell therapies for third parties, as well as a variety of related analytical services. The Company accounted for the MaSTherCell acquisition using the acquisition method in accordance with ASC 805. The operating results of MaSTherCell have been included in the Company’s consolidated financial statements for the period following the acquisition date. The Company preliminarily estimated fair values at the date of acquisition for the preliminary allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed as part of the MaSTherCell acquisition. The Company recognized, property, plant and equipment of $25.5 million, $51.0 million for identifiable intangible assets, $2.0 million for other net assets, and $7.7 million for deferred income tax liabilities. The remainder of the fair value, $252.5 million, was preliminarily allocated to goodwill. Goodwill is mainly comprised of the growth from an expected increase in capacity utilization, potential new customers, and advanced cell therapy development and manufacturing capabilities. During the measurement period ending no later than one year after the acquisition date, the Company will continue to obtain information to assist in finalizing the fair values of the net assets acquired, which may differ materially from these preliminary estimates. The amounts subject to finalization include working capital and income taxes. If any measurement period adjustment is material, the Company will record such adjustment, including any related impact on net income, in the reporting period in which the adjustment is determined. The Company expects to finalize its allocation over the next several months, but, in any event, within one year from the closing.

Goodwill

Goodwill	3 Months Ended
Goodwill	Sep. 30, 2020
Goodwill Disclosure [Abstract]
Goodwill	GOODWILL The following table summarizes the changes between June 30, 2020 and September 30, 2020 in the carrying amount of goodwill in total and by reporting segment: (Dollars in millions) Biologics Softgel & Oral Technologies Oral & Specialty Delivery Clinical Supply Services Total Balance at June 30, 2020 $ 1,462.2 $ 505.5 $ 354.7 $ 148.2 $ 2,470.6 Other (0.4) — — — (0.4) Foreign currency translation adjustments 8.6 6.1 3.1 2.4 20.2 Balance at September 30, 2020 $ 1,470.4 $ 511.6 $ 357.8 $ 150.6 $ 2,490.4 The Company recorded no impairment charge to goodwill in the current period.

Definite Lived Long-Lived Asset

Definite Lived Long-Lived Assets	3 Months Ended
Definite Lived Long-Lived Assets	Sep. 30, 2020
Intangible Assets Disclosure [Abstract]
Definite Lived Long-Lived Assets	DEFINITE-LIVED LONG-LIVED ASSETS The Company’s definite-lived long-lived assets include property, plant, and equipment as well as intangible assets with definite lives. Refer to Note 17, Supplemental Balance Sheet Information for details related to property, plant, and equipment. The details of other intangibles, net as of September 30, 2020 and June 30, 2020 are as follows: (Dollars in millions) Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value September 30, 2020 Amortized intangibles: Core technology 19 years $ 136.9 $ (86.4) $ 50.5 Customer relationships 14 years 1,027.4 (268.4) 759.0 Product relationships 11 years 273.8 (223.1) 50.7 Other 5 years 15.6 (5.5) 10.1 Total intangible assets $ 1,453.7 $ (583.4) $ 870.3 (Dollars in millions) Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value June 30, 2020 Amortized intangibles: Core technology 19 years $ 134.5 $ (83.0) $ 51.5 Customer relationships 14 years 1,021.3 (248.0) 773.3 Product relationships 11 years 270.4 (217.5) 52.9 Other 5 years 15.5 (4.5) 11.0 Total intangible assets $ 1,441.7 $ (553.0) $ 888.7 Amortization expense related to definite-lived long-lived assets was $23.0 million and $21.5 million for the three months ended September 30, 2020 and September 30, 2019, respectively. Future amortization expense related to definite-lived long-lived assets for the next five fiscal years is estimated to be: (Dollars in millions) Remainder 2022 2023 2024 2025 2026 Amortization expense $ 68.6 $ 90.7 $ 90.1 $ 89.5 $ 88.5 $ 81.4

Long-Term Obligations and Other

Long-Term Obligations and Other Short-Term Borrowings	3 Months Ended
Long-Term Obligations and Other Short-Term Borrowings	Sep. 30, 2020
Debt Disclosure [Abstract]
Long-Term Obligations and Other Short-Term Borrowings	LONG-TERM OBLIGATIONS AND SHORT-TERM BORROWINGS Long-term obligations and short-term borrowings consisted of the following at September 30, 2020 and June 30, 2020: (Dollars in millions) Maturity as of September 30, 2020 September 30, 2020 June 30, 2020 Senior secured credit facilities U.S. dollar-denominated term loan facility May 2026 $ 926.5 $ 928.5 U.S. dollar-denominated 4.875% senior notes due 2026 January 2026 445.6 445.4 U.S. dollar-denominated 5.00% senior notes due 2027 July 2027 493.3 493.1 Euro-denominated 2.375% senior notes due 2028 March 2028 944.6 909.9 Deferred purchase consideration October 2021 98.2 97.5 Finance lease obligations 2020 to 2044 149.5 142.2 Other obligations 2020 to 2024 1.0 1.4 Total $ 3,058.7 $ 3,018.0 Less: current portion of long-term obligations and other short-term 73.4 72.9 Long-term obligations, less current portion $ 2,985.3 $ 2,945.1 Deferred Purchase Consideration In connection with the acquisition of Catalent Indiana, LLC in October 2017, $200.0 million of the $950.0 million aggregate nominal purchase price is payable in $50.0 million installments on each of the first four anniversaries of the closing date. The Company made installment payments in October 2018, in October 2019, and, following the end of the first quarter of fiscal 2021, in October 2020. The balance of the deferred purchase consideration was recorded at fair value as of the acquisition date, with the difference between the remaining nominal amount and the fair value treated as imputed interest. Measurement of the Fair Value of Debt The measurement of the estimated fair value of the Company’s senior secured credit facilities and other senior indebtedness is classified as a Level 2 determination in the fair-value hierarchy and is calculated by using a discounted cash flow model with the market interest rate as a significant input. The carrying amounts and the estimated fair values of the Company’s principal categories of debt as of September 30, 2020 and June 30, 2020 are as follows: September 30, 2020 June 30, 2020 (Dollars in millions) Fair Value Measurement Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value U.S. dollar-denominated 4.875% senior notes due 2026 Level 2 445.6 463.4 445.4 463.6 U.S. dollar-denominated 5.00% senior notes Level 2 493.3 533.7 493.1 537.9 Euro-denominated 2.375% senior notes due 2028 Level 2 944.6 894.9 909.9 844.1 Senior secured credit facilities & other Level 2 1,175.2 1,177.8 1,169.6 1,160.1 Total $ 3,058.7 $ 3,069.8 $ 3,018.0 $ 3,005.7

Earnings Per Share

Earnings Per Share	3 Months Ended
Earnings Per Share	Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The Company computes earnings per share of the Company’s Common Stock using the two-class method required due to the participating nature of the Series A Preferred Stock (as defined and discussed in Note 14, Redeemable Preferred Stock—Series A Preferred ). Diluted net income per share is computed using the weighted average number of shares of Common Stock outstanding plus the weighted average number of shares of Common Stock that would be issued assuming exercise or conversion of all potentially dilutive instruments. Dilutive securities having an anti-dilutive effect on diluted net income per share are excluded from the calculation. The dilutive effect of the securities that are issuable under the Company’s equity incentive plans are reflected in diluted earnings per share by application of the treasury stock method. The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three months ended September 30, 2020 and 2019, respectively, are as follows (in millions, except share and per share data): Three Months Ended (Dollars in millions) 2020 2019 Net earnings $ 82.4 $ 0.1 Less: Net earnings attributable to preferred shareholders (13.6) (8.1) Net earnings/(loss) attributable to common shareholders $ 68.8 $ (8.0) Weighted average shares outstanding 164,088,003 145,663,115 Weighted average dilutive securities issuable-stock plans 2,441,035 — Total weighted average diluted shares outstanding 166,529,038 145,663,115 Earnings (loss) per share: Basic $ 0.42 $ (0.05) Diluted $ 0.41 $ (0.05) The computation of diluted earnings per share for the three months ended September 30, 2020 excludes the effect of approximately 13.1 million “if-converted” shares of Common Stock potentially issuable on the conversion of Series A Preferred Stock, as those shares would be anti-dilutive. The computation of diluted earnings per share for the three months ended September 30, 2019 also excludes the effect of these shares, as well as the effect of the assumed exercise of stock options, as all such shares would be anti-dilutive in a period with a net loss attributable to common shareholders.

Other (Income)_ Expense, Net

Other (Income)/ Expense, Net	3 Months Ended
Other (Income)/ Expense, Net	Sep. 30, 2020
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure [Text Block]	OTHER (INCOME)/EXPENSE, NET The components of other (income)/expense, net for the three months ended September 30, 2020 and 2019 are as follows: Three Months Ended (Dollars in millions) 2020 2019 Other (income)/expense, net Debt refinancing costs $ — $ 0.1 Foreign currency gains (1) (0.6) (3.1) Other (2) (10.6) 7.9 Total other (income)/expense, net $ (11.2) $ 4.9 (1) Foreign currency remeasurement gains include both cash and non-cash transactions. (2) Included within Other for the three months ended September 30, 2020 and 2019 is an unrealized gain of $9.0 million and an unrealized loss of $8.9 million, respectively, each related to the fair value of the derivative liability associated with the Series A Preferred Stock.

Restructuring and Other Costs

Restructuring and Other Costs	3 Months Ended
Restructuring and Other Costs	Sep. 30, 2020
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	RESTRUCTURING AND OTHER COSTS From time to time, the Company has implemented plans to restructure certain operations, both domestically and internationally. The restructuring plans focused on various aspects of operations, including closing and consolidating certain manufacturing operations, rationalizing headcount and aligning operations in a strategic and more cost-efficient structure. In addition, the Company may incur restructuring charges in the future in cases where a material change in the scope of operation with its business occurs. Employee-related costs consist primarily of severance costs and also include outplacement services provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. Facility exit and other costs consist of accelerated depreciation, equipment relocation costs and costs associated with planned facility expansions and closures to streamline Company operations. The restructuring costs for the three months ended September 30, 2020 and 2019 were $0.9 million and $0.7 million, respectively.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	3 Months Ended
Derivative Instruments and Hedging Activities	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES The Company is exposed to fluctuations in the applicable exchange rate on its investments in operations outside the U.S. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated its exposure from its investments in its European operations by denominating a portion of its debt in euros. At September 30, 2020, the Company had euro-denominated debt outstanding of $944.6 million (U.S. dollar equivalent) that is designated and qualifies as a hedge of a net investment in foreign operations. For non-derivatives designated and qualifying as net investment hedges, the translation gains or losses are reported in accumulated other comprehensive income/(loss) as part of the cumulative translation adjustment. The non-hedge portions of the euro-denominated debt translation gains or losses are reported in the consolidated statement of operations. The following table includes net investment hedge activity during the three months ended September 30, 2020 and 2019. Three Months Ended (Dollars in millions) 2020 2019 Unrealized foreign exchange gain/(loss) within other comprehensive income $ (32.4) $ 20.3 Unrealized foreign exchange gain/(loss) within statement of operations $ (1.9) $ 9.7 The net accumulated loss on the instrument designated as a hedge as of September 30, 2020 within other comprehensive income/(loss) was approximately $30.1 million. Amounts are reclassified out of accumulated other comprehensive income/(loss) into earnings when the entity to which the gains and losses relate is either sold or substantially liquidated. Preferred Stock Derivative Liability As discussed in Note 14, Redeemable Preferred Stock—Series A Preferred, in May 2019, the Company issued shares of Series A Preferred Stock in exchange for net proceeds of $646.3 million after taking into account the $3.7 million issuance cost. The dividend rate used to determine the amount of the quarterly dividend payable on shares of the Series A Preferred Stock is subject to adjustment so as to provide holders of shares of Series A Preferred Stock with certain protections against a decline in the trading price of shares of Common Stock. The Company determined that this feature should be accounted for as a derivative liability, since the feature fluctuates inversely to changes in the trading price and is also linked to the performance of the S&P 500 stock index. Accordingly, the Company bifurcated the adjustable dividend feature from the remainder of the Series A Preferred Stock and accounted for this feature as a derivative liability at fair value. The Company will recognize changes in the fair value of the derivative liability in the consolidated statements of operations for each reporting period. The fair value was determined using an option pricing methodology, specifically both a Monte Carlo simulation and a binomial lattice model. The methodology incorporates the terms and conditions of the preferred stock arrangement, historical stock price volatility, the risk-free interest rate, a credit spread based on the yield indexes of high-yield bonds, and the trading price of shares of the Common Stock. The calculation of the estimated fair value of the derivative liability is highly sensitive to changes in unobservable inputs, such as the expected volatility and the Company’s specific credit spread. The Company recorded a gain of $9.0 million on the change in the estimated fair value of the derivative liability from June 30, 2020 through September 30, 2020, primarily related to volatility in the price of the Company’s Common Stock that is used to estimate the fair value, which is reflected as a non-operating expense in the consolidated statements of operations. The fair value of the derivative liability as of September 30, 2020 was $14.6 million. The fair value is classified as Level 3 in the fair-value hierarchy due to the significant management judgment required for the assumptions underlying the calculation of value. The following table sets forth a summary of changes in the estimated fair value of the derivative liability: ( Dollars in millions) Fair Value Measurements of Balance at June 30, 2020 $ 23.6 Change in estimated fair value of Series A Preferred Stock derivative liability (9.0) Balance at September 30, 2020 $ 14.6 Interest-Rate Swap Pursuant to its interest rate and risk management strategy, in April 2020, Operating Company entered into an interest-rate swap agreement with Bank of America N.A. as a hedge against the economic effect of a portion of the variable interest obligation associated with its U.S dollar-denominated term loans under its senior secured credit facilities, so that the interest payable on that portion of the debt becomes fixed at a certain rate, thereby reducing the impact of future interest rate changes on future interest expense. As a result of entering into the interest-rate swap agreement, the floating portion of the applicable rate on $500.0 million of the term loans is now effectively fixed at 1.26%, for a total fixed rate of 3.51%. The interest-rate swap agreement qualifies for and is designated as a cash-flow hedge. The Company evaluates hedge effectiveness at the inception of the hedge and on an ongoing basis. The fair value of the interest-rate swap agreement is determined at the end of each reporting period based on valuation models that use interest rate yield curves and discount rates as inputs. The discount rates are based on U.S. deposit or U.S. Treasury rates. The significant inputs used in the valuation models are readily available in public markets or can be derived from observable market transactions, and, therefore, the valuation has been classified as a Level 2 in the fair-value hierarchy. The estimated fair value of the interest rate swap as of September 30, 2020 and as of June 30, 2020 was reported as a derivative liability of $3.8 million and $3.7 million, respectively, within other liabilities in the consolidated balance sheets. The cash flows associated with the interest-rate swap are reported in net cash provided by operating activities in the consolidated statements of cash flows. The unrealized loss or unrealized gain from the mark-to-market of the interest rate swap valuation during the three months ended September 30, 2020 and the fiscal year ended June 30, 2020 was immaterial in each period.

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company accounts for income taxes in accordance with ASC 740, Income Taxes . Generally, fluctuations in the effective tax rate are primarily due to changes in U.S. and non-U.S. pretax income resulting from the Company’s business mix and changes in the tax impact of special items and other discrete tax items, which may have unique tax implications depending on the nature of the item. Such discrete items include, but are not limited to, changes in foreign statutory tax rates, the amortization of certain assets, the tax impact of changes in the Company’s unrecognized tax benefit reserves and the tax impact of certain equity compensation. In the normal course of business, the Company is subject to examination by taxing authorities around the world, including such major jurisdictions as the United States, Germany, and the United Kingdom. The Company is no longer subject to examinations by the relevant tax authorities for years prior to fiscal year 2009. ASC 740 includes guidance on the accounting for uncertainty in income taxes recognized in the financial statements. This standard provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolution of any related appeal or litigation process, based on the technical merits. As of September 30, 2020 and June 30, 2020, the Company had an aggregate of $4.5 million and $5.6 million, respectively, of uncertain tax positions (including accrued interest and penalties). As of these dates, $3.2 million and $4.4 million, respectively, represent the amount of unrecognized tax benefits, which, if recognized, would favorably affect the effective income tax rate. The reduction to unrecognized tax benefits is primarily driven by a settlement of Italian income taxes that occurred in the current period. Interest and penalties related to uncertain tax positions are recognized as a component of income tax expense. The Company recorded a benefit for income taxes for the three months ended September 30, 2020 of $15.0 million relative to earnings before income taxes of $67.4 million. The Company recorded a benefit for income taxes for the three

Employee Retirement Benefit Pla

Employee Retirement Benefit Plans	3 Months Ended
Employee Retirement Benefit Plans	Sep. 30, 2020
Retirement Benefits [Abstract]
Employee Retirement Benefit Plans	EMPLOYEE RETIREMENT BENEFIT PLANS Components of the Company’s net periodic benefit costs are as follows: Three Months Ended (Dollars in millions) 2020 2019 Components of net periodic benefit cost: Selling, general, and administrative expenses: Service cost $ 1.0 $ 0.6 Other (income)/expense, net: Interest cost 1.0 1.7 Expected return on plan assets (2.4) (2.7) Amortization (1) 0.7 0.8 Net amount recognized $ 0.3 $ 0.4 (1) Amount represents the amortization of unrecognized actuarial gains/(losses). As previously disclosed, the Company notified the trustees of a multi-employer pension plan of its withdrawal from participation in such plan in fiscal 2012. The actuarial review process administered by the plan trustees ended in fiscal 2015. The liability reported reflects the present value of the Company’s expected future long-term obligations. The estimated discounted value of the projected contributions related to such plans was $38.6 million as of September 30, 2020 and June 30, 2020, and is included within pension liability on the consolidated balance sheets. The annual cash impact associated with the Company’s obligations in such plan is approximately $1.7 million per year.

Equity and Accumulated Other Co

Equity and Accumulated Other Comprehensive Income (Loss)	3 Months Ended
Equity and Accumulated Other Comprehensive Income (Loss)	Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	EQUITY AND ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) Description of Capital Stock The Company is authorized to issue 1,000,000,000 shares of its Common Stock and 100,000,000 shares of preferred stock, par value $0.01 per share. In accordance with the Company’s amended and restated certificate of incorporation, each share of Common Stock has one vote, and the Common Stock votes together as a single class. Recent Public Offerings of its Common Stock On June 15, 2020, the Company completed a public offering of its Common Stock (the “June 2020 Equity Offering”), in which the Company sold 7.7 million shares of Common Stock at a price of $70.72 per share, net of underwriting discounts and commissions. The Company obtained total net proceeds from the June 2020 Equity Offering of $547.5 million after the payment of associated offering expenses. The net proceeds of the June 2020 Equity Offering were used to repay $200.0 million of precautionary borrowings from the third quarter of fiscal 2020 under Operating Company's revolving credit facility, with the remainder available for general corporate purposes. On July 10, 2020, the underwriter for the June 2020 Equity Offering exercised its over-allotment option on 1.2 million additional shares, resulting in supplemental net proceeds of $81.8 million from the June 2020 Equity Offering, which was recorded in the current period. On February 6, 2020, the Company completed the February 2020 Equity Offering, in which the Company sold 8.4 million shares of Common Stock at a price of $58.58 per share, net of underwriting discounts and commissions. The Company obtained total net proceeds from the February 2020 Equity Offering of $494.2 million. The net proceeds of the February 2020 Equity Offering were used to repay $100.0 million of borrowings earlier in the quarter under Operating Company's revolving credit facility and pay the consideration for the MaSTherCell acquisition due at its closing, with the remainder available for general corporate purposes. Effect of Restricted Stock Shares of Common Stock outstanding include shares of unvested restricted stock. Unvested restricted stock included in reportable shares outstanding was 0.2 million shares as of September 30, 2020. Shares of unvested restricted stock are excluded from the calculation of basic weighted average shares outstanding, but their dilutive impact is added back in the calculation of diluted weighted average shares outstanding, except when the effect would be anti-dilutive. Accumulated Other Comprehensive Loss The components of the changes in the cumulative translation adjustment, derivatives and hedges, and minimum pension liability for the three months ended September 30, 2020 and 2019 are presented below. Three Months Ended (Dollars in millions) 2020 2019 Foreign currency translation adjustments: Net investment hedge $ (32.4) $ 20.3 Long-term intercompany loans 6.3 (6.5) Translation adjustments 35.4 (32.3) Total foreign currency translation adjustment, pretax 9.3 (18.5) Tax expense/(benefit) (6.6) 3.3 Total foreign currency translation adjustment, net of tax $ 15.9 $ (21.8) Net change in derivatives and hedges: Net loss recognized during the period $ (0.1) $ — Total derivatives and hedges, pretax (0.1) — Tax expense/(benefit) — — Net change in derivatives and hedges, net of tax $ (0.1) $ — Net change in minimum pension liability Net gain/(loss) recognized during the period $ 0.7 $ (0.6) Total pension liability, pretax 0.7 (0.6) Tax expense/(benefit) 0.2 (0.3) Net change in minimum pension liability, net of tax $ 0.5 $ (0.3) For the three months ended September 30, 2020, the changes in accumulated other comprehensive loss, net of tax by component are as follows: (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Other Total Balance at June 30, 2020 $ (335.1) $ (47.5) $ (2.6) $ (1.1) $ (386.3) Other comprehensive income before 15.9 — (0.1) — 15.8 Amounts reclassified from accumulated other — 0.5 — — 0.5 Net current period other comprehensive income 15.9 0.5 (0.1) — 16.3 Balance at September 30, 2020 $ (319.2) $ (47.0) $ (2.7) $ (1.1) $ (370.0)

Redeemable Preferred Stock - Se

Redeemable Preferred Stock - Series A Preferred	3 Months Ended
Redeemable Preferred Stock - Series A Preferred	Sep. 30, 2020
Equity [Abstract]
Preferred Stock [Text Block]	REDEEMABLE PREFERRED STOCK — SERIES A PREFERRED In May 2019, the Company designated 1,000,000 shares of its preferred stock, par value $0.01, as its Series A Convertible Preferred Stock (the “Series A Preferred Stock”), pursuant to a certificate of designation of preferences, rights, and limitations (as amended, the “Certificate of Designation”) filed with the Delaware Secretary of State, and issued and sold 650,000 shares of the Series A Preferred Stock for an aggregate purchase price of $650.0 million , to affiliates of Leonard Green & Partners, L.P., each share having an initial stated value of $1,000 (as such value may be adjusted in accordance with the terms of the Certificate of Designation). The Series A Preferred Stock ranks senior to the Company’s Common Stock with respect to dividend rights and rights upon the voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company. Proceeds from the offering of the Series A Preferred Stock, net of stock issuance costs, were $646.3 million . Of the net proceeds, $39.7 million was allocated to the dividend-adjustment feature at its issuance and separately accounted for as a derivative liability, as disclosed in Note 10, Derivative Instruments and Hedging Activities ; thus, the proceeds of the issuance were allocated as follows: (Dollars in millions) Issuance of Series A Preferred Stock $ 650.0 Stock issuance costs (3.7) Net of stock issuance costs 646.3 Derivative liability (portion of preferred stock allocated to dividend-adjustment feature at inception - see Note 10) (39.7) Net proceeds from Series A Preferred Stock issuance $ 606.6 Any change in the fair value of derivative liability during a fiscal quarter is recorded as a non-operating expenses in the consolidated statement of operations for that quarter. See Note 10, Derivative Instruments and Hedging Activities for detail concerning the change in fair value during the three months ended September 30, 2020 .

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will have a material adverse effect on the Company’s consolidated financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise. From time to time, the Company receives subpoenas or requests for information relating to the business practices and activities of customers or suppliers from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties engaged in patent infringement, antitrust, tort, and other litigation. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred. The Company expects to incur costs in future periods in connection with future requests.

Segment Information

Segment Information	3 Months Ended
Segment Information	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company now conducts its business within the following operating segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Company evaluates the performance of its segments based on segment earnings before other (expense)/income, impairments, restructuring costs, interest expense, income tax expense/(benefit), and depreciation and amortization ( “ Segment EBITDA ” ). “ EBITDA from operations ” is consolidated earnings from operations before interest expense, income tax expense/(benefit), and depreciation and amortization. Segment EBITDA and EBITDA from operations are not defined in U.S. GAAP and may not be comparable to similarly titled measures used by other companies. The following tables include net revenue and Segment EBITDA for each of the Company's current reporting segments during the three months ended September 30, 2020 and 2019: (Dollars in millions) Three Months Ended 2020 2019 Net revenue: Biologics $ 377.1 $ 188.6 Softgel and Oral Technologies 221.1 263.7 Oral and Specialty Delivery 158.3 132.6 Clinical Supply Services 92.7 84.6 Inter-segment revenue elimination (3.5) (4.8) Net revenue $ 845.7 $ 664.7 (Dollars in millions) Three Months Ended 2020 2019 Segment EBITDA reconciled to net earnings: Biologics $ 106.5 $ 35.8 Softgel and Oral Technologies 37.8 46.4 Oral and Specialty Delivery 21.4 27.7 Clinical Supply Services 25.0 21.6 Sub-Total $ 190.7 $ 131.5 Reconciling items to net earnings Unallocated costs (1) (28.9) (41.4) Depreciation and amortization (69.1) (60.6) Interest expense, net (25.3) (36.3) Income tax expense/(benefit) 15.0 6.9 Net earnings $ 82.4 $ 0.1 (1) Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: Three Months Ended (Dollars in millions) 2020 2019 Impairment charges and gain/(loss) on sale of assets $ (1.8) $ 0.2 Stock-based compensation (18.7) (16.6) Restructuring and other special items (a) (4.9) (11.8) Other income/(expense), net (b) 11.2 (4.9) Unallocated corporate costs, net (14.7) (8.3) Total unallocated costs $ (28.9) $ (41.4) (a) Restructuring and other special items during the three months ended September 30, 2020 include transaction and integration costs associated with the Anagni and MaSTherCell acquisitions, the disposal of a site in Australia, and other restructuring initiatives across the Company’s network of sites. Restructuring and other special items during the three months ended September 30, 2019 include transaction and integration costs associated with the Company’s cell and gene therapy acquisitions. (b) Refer to Note 8, Other (income)/expense, net, for details of financing charges and foreign currency translation adjustments recorded within other income/(expense), net. The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements. (Dollars in millions) September 30, June 30, Assets: Biologics $ 3,995.1 $ 3,775.0 Softgel and Oral Technologies 1,527.8 1,501.8 Oral and Specialty Delivery 1,228.3 1,247.4 Clinical Supply Services 460.6 451.2 Corporate and eliminations 772.4 801.1 Total assets $ 7,984.2 $ 7,776.5

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	3 Months Ended
Supplemental Balance Sheet Information	Sep. 30, 2020
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Information	SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental balance sheet information at September 30, 2020 and June 30, 2020 is detailed in the following tables. Inventories Work-in-process and inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions) September 30, June 30, Raw materials and supplies $ 278.8 $ 222.6 Work-in-process 135.0 123.2 Total inventories, gross 413.8 345.8 Inventory cost adjustment (29.5) (22.0) Inventories $ 384.3 $ 323.8 Prepaid expenses and other Prepaid expenses and other consist of the following: (Dollars in millions) September 30, June 30, Prepaid expenses $ 49.9 $ 28.6 Contract assets 116.2 61.4 Spare parts supplies 22.4 23.1 Prepaid income tax 18.1 15.0 Non-U.S. value-added tax 23.5 19.0 Other current assets 33.8 30.8 Prepaid expenses and other $ 263.9 $ 177.9 Property, plant, and equipment, net Property, plant, and equipment, net consist of the following: (Dollars in millions) September 30, June 30, Land, buildings, and improvements $ 1,277.1 $ 1,250.9 Machinery and equipment 1,290.6 1,233.6 Furniture and fixtures 22.6 20.9 Construction in progress 546.4 440.0 Property, plant, and equipment, at cost 3,136.7 2,945.4 Accumulated depreciation (1,101.2) (1,044.6) Property, plant, and equipment, net $ 2,035.5 $ 1,900.8 Depreciation expense was $46.1 million for the three months ended September 30, 2020, and $39.1 million for the three months ended September 30, 2019. Depreciation expense includes amortization of assets related to finance leases. The Company charges repairs and maintenance costs to expense as incurred. The Company capitalized interest cost of $6.2 million for the three months ended September 30, 2020. Other accrued liabilities Other accrued liabilities consist of the following: (Dollars in millions) September 30, June 30, Accrued employee-related expenses $ 140.3 $ 140.8 Restructuring accrual 2.4 2.8 Accrued interest 12.2 29.1 Contract liability 229.4 191.0 Accrued income tax — 4.5 Other accrued liabilities and expenses 132.6 131.1 Other accrued liabilities $ 516.9 $ 499.3

Subsequent Events (Notes)

Subsequent Events (Notes)	3 Months Ended
Subsequent Events (Notes)	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	SUBSEQUENT EVENTSOn October 28, 2020, the Company entered into an agreement to acquire all of the shares of Skeletal Cell Therapy Support SA (“Skeletal”) from Bone Therapeutics SA (“Bone”) for €12.0 million, subject to customary adjustments, as well as related supply agreements with Bone. Skeletal leases and operates a cell therapy manufacturing facility in Gosselies, Belgium. Upon closing, the facility and operations will become part of the Company’s Biologics business unit, expanding the Company’s cell therapy capacity for clinical and commercial supply. The agreement is subject to customary closing conditions and is expected to close during the second quarter of fiscal 2021.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ( “U.S. GAAP ” ) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending June 30, 2021. The consolidated balance sheet at June 30, 2020 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information on the Company's accounting policies and footnotes, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2020 filed with the Securities and Exchange Commission (the “ SEC ” ).
Foreign Currency Translation	Foreign Currency Translation The financial statements of the Company’s operations are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of operations outside the U.S. into U.S. dollars are accumulated as a component of other comprehensive income/(loss) utilizing period-end exchange rates. Since July 1, 2018, the Company has accounted for its Argentine operations as highly inflationary.
Research and Development Costs	Research and Development Costs The Company expenses research and development costs as incurred. Research and development costs amounted to $6.4 million and $4.6 million for the three months ended September 30, 2020 and 2019, respectively.
Recent Financial Accounting Standards	Recent Financial Accounting Standards Recently Adopted Accounting Standards In August 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted the guidance on July 1, 2020. The guidance did not have a material impact on the Company’s financial condition or results of operations. In August 2018, the FASB issued ASU 2018-13 , Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirement for Fair Value Measurement , which changes the disclosure requirements on fair value measurements in Accounting Standards Codification ( “ ASC ”) 820 Fair Value Measurement . The guidance eliminates certain disclosure requirements that are no longer considered cost beneficial and adds new disclosure requirements for Level 3 fair value measurements. The Company adopted the guidance on July 1, 2020. The guidance did not have a material impact on the Company’s financial condition or results of operations. In June 2016, the FASB issued ASU 2016-13 , Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which introduces a new accounting model known as Credit Expected Credit Losses ( “ CECL ” ). CECL requires earlier recognition of credit losses on financial assets, while also providing additional transparency about credit risk. The CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses for financial assets at the time they are originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. This model replaces the multiple existing impairment models in current U.S. GAAP, which generally require that a loss be incurred before it is recognized. The new standard applies to receivables arising from revenue transactions such as contract assets and accounts receivables. The Company adopted the amended guidance using a modified retrospective approach on July 1, 2020. The amended guidance did not have a material impact on the Company’s financial condition or results of operations. New Accounting Standards Not Adopted as of September 30, 2020 In March 2020, the FASB issued ASU 2020-04 , Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional guidance to ease the potential burden in accounting for the discontinuation of a reference rate such as LIBOR, formerly known as the London Interbank Offered Rate, because of reference rate reform. The expedients and exceptions provided by the guidance do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. The ASU is effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12 , Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which eliminates certain exceptions related to the incremental approach for intra-period allocation, deferred tax recognition requirement for changes in equity method investments and foreign subsidiaries, and methodology for calculating income taxes in an interim period. The guidance also simplifies certain aspects of the accounting for franchise taxes, the accounting for step-up in the tax basis of goodwill, and accounting for the change in the enacted change in tax laws or rates. The ASU will be effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.

Revenue from Contract with Cust

Revenue from Contract with Customer (Policies)	3 Months Ended
Revenue from Contract with Customer (Policies)	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Policy Text Block]	REVENUE RECOGNITION The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers . The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. The Company measures the revenue from customers based on the consideration specified in its contracts, excluding any sales incentive or amount collected on behalf of a third party. The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material. The following tables allocate revenue, for the three months ended September 30, 2020 and September 30, 2019, by type of activity and reporting segment (in millions): Three Months Ended September 30, 2020 Biologics Softgel & Oral Technologies Oral & Specialty Delivery Clinical Supply Services Total Manufacturing & commercial product supply $ 89.9 $ 190.6 $ 103.5 $ — $ 384.0 Development services 287.2 30.5 54.8 — 372.5 Clinical supply services — — — 92.7 92.7 Total $ 377.1 $ 221.1 $ 158.3 $ 92.7 $ 849.2 Inter-segment revenue elimination (3.5) Combined net revenue $ 845.7 Three Months Ended September 30, 2019 Biologics Softgel & Oral Technologies Oral & Specialty Delivery Clinical Supply Services Total Manufacturing & commercial product supply $ 64.4 $ 242.0 $ 76.0 $ — $ 382.4 Development services 124.2 21.7 56.6 — 202.5 Clinical supply services — — — 84.6 84.6 Total $ 188.6 $ 263.7 $ 132.6 $ 84.6 $ 669.5 Inter-segment revenue elimination (4.8) Combined net revenue $ 664.7 The following table allocates revenue by the location where the goods were made or the service performed: Three Months Ended (Dollars in millions) 2020 2019 United States $ 516.9 $ 362.3 Europe 281.4 210.1 International Other 68.8 110.9 Elimination of revenue attributable to multiple locations (21.4) (18.6) Total $ 845.7 $ 664.7 Contract Liabilities Contract liabilities relate to cash consideration that the Company receives in advance of satisfying the related performance obligations. The contract liabilities balance as of September 30, 2020 and June 30, 2020 are as follows: (Dollars in millions) Balance at June 30, 2020 $ 218.4 Balance at September 30, 2020 $ 243.9 Revenue recognized in the period from July 1 through September 30, 2020: Amounts included in contract liability at the beginning of the period $ 48.2 Contract Assets C ontract assets primarily relate to the Company's conditional right to receive consideration for services that have been performed for the customer as of September 30, 2020 relating to its development services but had not yet been invoiced as of September 30, 2020. Contract assets are transferred to trade receivables, net when the Company’s right to receive the consideration becomes unconditional. Contract assets totaled $116.2 million and $61.4 million as of September 30, 2020 and June 30, 2020, respectively. Contract assets are included in Prepaid expenses and other as they are expected to be transferred to trade receivables within 12 months of September 30, 2020. Receivables and Allowance for Doubtful Accounts

Revenue Recognition Revenue Rec

Revenue Recognition Revenue Recognition (Tables)	3 Months Ended
Revenue Recognition Revenue Recognition (Tables)	Sep. 30, 2020
Geographical [Member]
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue	The following table allocates revenue by the location where the goods were made or the service performed: Three Months Ended (Dollars in millions) 2020 2019 United States $ 516.9 $ 362.3 Europe 281.4 210.1 International Other 68.8 110.9 Elimination of revenue attributable to multiple locations (21.4) (18.6) Total $ 845.7 $ 664.7
Product and Service[Member]
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue	The following tables allocate revenue, for the three months ended September 30, 2020 and September 30, 2019, by type of activity and reporting segment (in millions): Three Months Ended September 30, 2020 Biologics Softgel & Oral Technologies Oral & Specialty Delivery Clinical Supply Services Total Manufacturing & commercial product supply $ 89.9 $ 190.6 $ 103.5 $ — $ 384.0 Development services 287.2 30.5 54.8 — 372.5 Clinical supply services — — — 92.7 92.7 Total $ 377.1 $ 221.1 $ 158.3 $ 92.7 $ 849.2 Inter-segment revenue elimination (3.5) Combined net revenue $ 845.7 Three Months Ended September 30, 2019 Biologics Softgel & Oral Technologies Oral & Specialty Delivery Clinical Supply Services Total Manufacturing & commercial product supply $ 64.4 $ 242.0 $ 76.0 $ — $ 382.4 Development services 124.2 21.7 56.6 — 202.5 Clinical supply services — — — 84.6 84.6 Total $ 188.6 $ 263.7 $ 132.6 $ 84.6 $ 669.5 Inter-segment revenue elimination (4.8) Combined net revenue $ 664.7

Revenue Recognition Contractual

Revenue Recognition Contractual Liabilities (Tables)	3 Months Ended
Revenue Recognition Contractual Liabilities (Tables)	Sep. 30, 2020
Revenue Recognition and Deferred Revenue [Abstract]
Contractual Liabilities	e contract liabilities balance as of September 30, 2020 and June 30, 2020 are as follows: (Dollars in millions) Balance at June 30, 2020 $ 218.4 Balance at September 30, 2020 $ 243.9 Revenue recognized in the period from July 1 through September 30, 2020: Amounts included in contract liability at the beginning of the period $ 48.2

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
Goodwill (Tables)	Sep. 30, 2020
Goodwill Disclosure [Abstract]
Goodwill - Rollforward	The following table summarizes the changes between June 30, 2020 and September 30, 2020 in the carrying amount of goodwill in total and by reporting segment: (Dollars in millions) Biologics Softgel & Oral Technologies Oral & Specialty Delivery Clinical Supply Services Total Balance at June 30, 2020 $ 1,462.2 $ 505.5 $ 354.7 $ 148.2 $ 2,470.6 Other (0.4) — — — (0.4) Foreign currency translation adjustments 8.6 6.1 3.1 2.4 20.2 Balance at September 30, 2020 $ 1,470.4 $ 511.6 $ 357.8 $ 150.6 $ 2,490.4 The Company recorded no impairment charge to goodwill in the current period.

Definite Lived Long-Lived Ass_2

Definite Lived Long-Lived Assets (Tables)	3 Months Ended
Definite Lived Long-Lived Assets (Tables)	Sep. 30, 2020
Intangible Assets Disclosure [Abstract]
Other Intangible Assets Subject to Amortization	The details of other intangibles, net as of September 30, 2020 and June 30, 2020 are as follows: (Dollars in millions) Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value September 30, 2020 Amortized intangibles: Core technology 19 years $ 136.9 $ (86.4) $ 50.5 Customer relationships 14 years 1,027.4 (268.4) 759.0 Product relationships 11 years 273.8 (223.1) 50.7 Other 5 years 15.6 (5.5) 10.1 Total intangible assets $ 1,453.7 $ (583.4) $ 870.3 (Dollars in millions) Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value June 30, 2020 Amortized intangibles: Core technology 19 years $ 134.5 $ (83.0) $ 51.5 Customer relationships 14 years 1,021.3 (248.0) 773.3 Product relationships 11 years 270.4 (217.5) 52.9 Other 5 years 15.5 (4.5) 11.0 Total intangible assets $ 1,441.7 $ (553.0) $ 888.7
Future Amortization Expense	Future amortization expense related to definite-lived long-lived assets for the next five fiscal years is estimated to be: (Dollars in millions) Remainder 2022 2023 2024 2025 2026 Amortization expense $ 68.6 $ 90.7 $ 90.1 $ 89.5 $ 88.5 $ 81.4

Long-Term Obligations and Oth_2

Long-Term Obligations and Other Short-Term Borrowings (Tables)	3 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Long-Term Obligations, Presented Net of Issue Discounts and Fees Paid to Lenders, and Other Short-Term Borrowings	Long-term obligations and short-term borrowings consisted of the following at September 30, 2020 and June 30, 2020: (Dollars in millions) Maturity as of September 30, 2020 September 30, 2020 June 30, 2020 Senior secured credit facilities U.S. dollar-denominated term loan facility May 2026 $ 926.5 $ 928.5 U.S. dollar-denominated 4.875% senior notes due 2026 January 2026 445.6 445.4 U.S. dollar-denominated 5.00% senior notes due 2027 July 2027 493.3 493.1 Euro-denominated 2.375% senior notes due 2028 March 2028 944.6 909.9 Deferred purchase consideration October 2021 98.2 97.5 Finance lease obligations 2020 to 2044 149.5 142.2 Other obligations 2020 to 2024 1.0 1.4 Total $ 3,058.7 $ 3,018.0 Less: current portion of long-term obligations and other short-term 73.4 72.9 Long-term obligations, less current portion $ 2,985.3 $ 2,945.1

Long-Term Obligations and Oth_3

Long-Term Obligations and Other Short-Term Borrowings Fair Value of Financial Instruments (Tables)	3 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule Of Carrying And Fair Value Of Financial Instruments Table	The carrying amounts and the estimated fair values of the Company’s principal categories of debt as of September 30, 2020 and June 30, 2020 are as follows: September 30, 2020 June 30, 2020 (Dollars in millions) Fair Value Measurement Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value U.S. dollar-denominated 4.875% senior notes due 2026 Level 2 445.6 463.4 445.4 463.6 U.S. dollar-denominated 5.00% senior notes Level 2 493.3 533.7 493.1 537.9 Euro-denominated 2.375% senior notes due 2028 Level 2 944.6 894.9 909.9 844.1 Senior secured credit facilities & other Level 2 1,175.2 1,177.8 1,169.6 1,160.1 Total $ 3,058.7 $ 3,069.8 $ 3,018.0 $ 3,005.7

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
Earnings Per Share (Tables)	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three months ended September 30, 2020 and 2019, respectively, are as follows (in millions, except share and per share data): Three Months Ended (Dollars in millions) 2020 2019 Net earnings $ 82.4 $ 0.1 Less: Net earnings attributable to preferred shareholders (13.6) (8.1) Net earnings/(loss) attributable to common shareholders $ 68.8 $ (8.0) Weighted average shares outstanding 164,088,003 145,663,115 Weighted average dilutive securities issuable-stock plans 2,441,035 — Total weighted average diluted shares outstanding 166,529,038 145,663,115 Earnings (loss) per share: Basic $ 0.42 $ (0.05) Diluted $ 0.41 $ (0.05) The computation of diluted earnings per share for the three months ended September 30, 2020 excludes the effect of approximately 13.1 million “if-converted” shares of Common Stock potentially issuable on the conversion of Series A Preferred Stock, as those shares would be anti-dilutive. The computation of diluted earnings per share for the three months ended September 30, 2019 also excludes the effect of these shares, as well as the effect of the assumed exercise of stock options, as all such shares would be anti-dilutive in a period with a net loss attributable to common shareholders.

Other Income and Expense (Table

Other Income and Expense (Tables)	3 Months Ended
Other Income and Expense (Tables)	Sep. 30, 2020
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense)	The components of other (income)/expense, net for the three months ended September 30, 2020 and 2019 are as follows: Three Months Ended (Dollars in millions) 2020 2019 Other (income)/expense, net Debt refinancing costs $ — $ 0.1 Foreign currency gains (1) (0.6) (3.1) Other (2) (10.6) 7.9 Total other (income)/expense, net $ (11.2) $ 4.9 (1) Foreign currency remeasurement gains include both cash and non-cash transactions. (2) Included within Other for the three months ended September 30, 2020 and 2019 is an unrealized gain of $9.0 million and an unrealized loss of $8.9 million, respectively, each related to the fair value of the derivative liability associated with the Series A Preferred Stock.

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities Net Investment Hedge Activity (Tables)	3 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Schedule of Net Investment Hedge in Accumulated Other Comprehensive Income (Loss) and Statement of Financial Performance	The following table includes net investment hedge activity during the three months ended September 30, 2020 and 2019. Three Months Ended (Dollars in millions) 2020 2019 Unrealized foreign exchange gain/(loss) within other comprehensive income $ (32.4) $ 20.3 Unrealized foreign exchange gain/(loss) within statement of operations $ (1.9) $ 9.7
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	The following table sets forth a summary of changes in the estimated fair value of the derivative liability: ( Dollars in millions) Fair Value Measurements of Balance at June 30, 2020 $ 23.6 Change in estimated fair value of Series A Preferred Stock derivative liability (9.0) Balance at September 30, 2020 $ 14.6

Employee Retirement Benefit P_2

Employee Retirement Benefit Plans (Tables)	3 Months Ended
Employee Retirement Benefit Plans (Tables)	Sep. 30, 2020
Retirement Benefits [Abstract]
Components of Company's Net Periodic Benefit Costs	Components of the Company’s net periodic benefit costs are as follows: Three Months Ended (Dollars in millions) 2020 2019 Components of net periodic benefit cost: Selling, general, and administrative expenses: Service cost $ 1.0 $ 0.6 Other (income)/expense, net: Interest cost 1.0 1.7 Expected return on plan assets (2.4) (2.7) Amortization (1) 0.7 0.8 Net amount recognized $ 0.3 $ 0.4 (1) Amount represents the amortization of unrecognized actuarial gains/(losses).

Equity and Accumulated Other _2

Equity and Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Comprehensive Income (Loss)	Accumulated Other Comprehensive Loss The components of the changes in the cumulative translation adjustment, derivatives and hedges, and minimum pension liability for the three months ended September 30, 2020 and 2019 are presented below. Three Months Ended (Dollars in millions) 2020 2019 Foreign currency translation adjustments: Net investment hedge $ (32.4) $ 20.3 Long-term intercompany loans 6.3 (6.5) Translation adjustments 35.4 (32.3) Total foreign currency translation adjustment, pretax 9.3 (18.5) Tax expense/(benefit) (6.6) 3.3 Total foreign currency translation adjustment, net of tax $ 15.9 $ (21.8) Net change in derivatives and hedges: Net loss recognized during the period $ (0.1) $ — Total derivatives and hedges, pretax (0.1) — Tax expense/(benefit) — — Net change in derivatives and hedges, net of tax $ (0.1) $ — Net change in minimum pension liability Net gain/(loss) recognized during the period $ 0.7 $ (0.6) Total pension liability, pretax 0.7 (0.6) Tax expense/(benefit) 0.2 (0.3) Net change in minimum pension liability, net of tax $ 0.5 $ (0.3)
Schedule of Accumulated Other Comprehensive Income (Loss)	For the three months ended September 30, 2020, the changes in accumulated other comprehensive loss, net of tax by component are as follows: (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Other Total Balance at June 30, 2020 $ (335.1) $ (47.5) $ (2.6) $ (1.1) $ (386.3) Other comprehensive income before 15.9 — (0.1) — 15.8 Amounts reclassified from accumulated other — 0.5 — — 0.5 Net current period other comprehensive income 15.9 0.5 (0.1) — 16.3 Balance at September 30, 2020 $ (319.2) $ (47.0) $ (2.7) $ (1.1) $ (370.0)

Equity (Tables)

Equity (Tables)	3 Months Ended
Equity (Tables)	Sep. 30, 2020
Equity [Abstract]
Schedule of Redeemable Preferred Stock	the proceeds of the issuance were allocated as follows: (Dollars in millions) Issuance of Series A Preferred Stock $ 650.0 Stock issuance costs (3.7) Net of stock issuance costs 646.3 Derivative liability (portion of preferred stock allocated to dividend-adjustment feature at inception - see Note 10) (39.7) Net proceeds from Series A Preferred Stock issuance $ 606.6

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
Segment Information (Tables)	Sep. 30, 2020
Segment Reporting [Abstract]
Net Revenue by Segment	(Dollars in millions) Three Months Ended 2020 2019 Net revenue: Biologics $ 377.1 $ 188.6 Softgel and Oral Technologies 221.1 263.7 Oral and Specialty Delivery 158.3 132.6 Clinical Supply Services 92.7 84.6 Inter-segment revenue elimination (3.5) (4.8) Net revenue $ 845.7 $ 664.7
Reconciliation of Earnings/(Loss) from Continuing Operations to EBITDA	(Dollars in millions) Three Months Ended 2020 2019 Segment EBITDA reconciled to net earnings: Biologics $ 106.5 $ 35.8 Softgel and Oral Technologies 37.8 46.4 Oral and Specialty Delivery 21.4 27.7 Clinical Supply Services 25.0 21.6 Sub-Total $ 190.7 $ 131.5 Reconciling items to net earnings Unallocated costs (1) (28.9) (41.4) Depreciation and amortization (69.1) (60.6) Interest expense, net (25.3) (36.3) Income tax expense/(benefit) 15.0 6.9 Net earnings $ 82.4 $ 0.1 (1) Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: Three Months Ended (Dollars in millions) 2020 2019 Impairment charges and gain/(loss) on sale of assets $ (1.8) $ 0.2 Stock-based compensation (18.7) (16.6) Restructuring and other special items (a) (4.9) (11.8) Other income/(expense), net (b) 11.2 (4.9) Unallocated corporate costs, net (14.7) (8.3) Total unallocated costs $ (28.9) $ (41.4) (a) Restructuring and other special items during the three months ended September 30, 2020 include transaction and integration costs associated with the Anagni and MaSTherCell acquisitions, the disposal of a site in Australia, and other restructuring initiatives across the Company’s network of sites. Restructuring and other special items during the three months ended September 30, 2019 include transaction and integration costs associated with the Company’s cell and gene therapy acquisitions. (b) Refer to Note 8, Other (income)/expense, net, for details of financing charges and foreign currency translation adjustments recorded within other income/(expense), net.
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements	The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements. (Dollars in millions) September 30, June 30, Assets: Biologics $ 3,995.1 $ 3,775.0 Softgel and Oral Technologies 1,527.8 1,501.8 Oral and Specialty Delivery 1,228.3 1,247.4 Clinical Supply Services 460.6 451.2 Corporate and eliminations 772.4 801.1 Total assets $ 7,984.2 $ 7,776.5

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	3 Months Ended
Supplemental Balance Sheet Information (Tables)	Sep. 30, 2020
Balance Sheet Related Disclosures [Abstract]
Inventory	Inventories Work-in-process and inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions) September 30, June 30, Raw materials and supplies $ 278.8 $ 222.6 Work-in-process 135.0 123.2 Total inventories, gross 413.8 345.8 Inventory cost adjustment (29.5) (22.0) Inventories $ 384.3 $ 323.8
Prepaid and Other Assets	Prepaid expenses and other Prepaid expenses and other consist of the following: (Dollars in millions) September 30, June 30, Prepaid expenses $ 49.9 $ 28.6 Contract assets 116.2 61.4 Spare parts supplies 22.4 23.1 Prepaid income tax 18.1 15.0 Non-U.S. value-added tax 23.5 19.0 Other current assets 33.8 30.8 Prepaid expenses and other $ 263.9 $ 177.9
Property and Equipment	Property, plant, and equipment, net Property, plant, and equipment, net consist of the following: (Dollars in millions) September 30, June 30, Land, buildings, and improvements $ 1,277.1 $ 1,250.9 Machinery and equipment 1,290.6 1,233.6 Furniture and fixtures 22.6 20.9 Construction in progress 546.4 440.0 Property, plant, and equipment, at cost 3,136.7 2,945.4 Accumulated depreciation (1,101.2) (1,044.6) Property, plant, and equipment, net $ 2,035.5 $ 1,900.8
Other Accrued Liabilities	Other accrued liabilities Other accrued liabilities consist of the following: (Dollars in millions) September 30, June 30, Accrued employee-related expenses $ 140.3 $ 140.8 Restructuring accrual 2.4 2.8 Accrued interest 12.2 29.1 Contract liability 229.4 191.0 Accrued income tax — 4.5 Other accrued liabilities and expenses 132.6 131.1 Other accrued liabilities $ 516.9 $ 499.3

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies Research and Development Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Research and Development Expense [Line Items]
Research and Development Expense	$ 6.4	$ 4.6

Revenue Recognition Disaggregat

Revenue Recognition Disaggregation of Revenue by type of activity and reporting segment (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Inter-segment revenue elimination	$ (3.5)	$ (4.8)
Net revenue	845.7	664.7
Biologics
Disaggregation of Revenue [Line Items]
Net revenue	377.1	188.6
Biologics \| Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	89.9	64.4
Biologics \| Development Services
Disaggregation of Revenue [Line Items]
Net revenue	287.2	124.2
Biologics \| Clinical Supply Services
Disaggregation of Revenue [Line Items]
Net revenue	0	0
Softgel and Oral Technologies
Disaggregation of Revenue [Line Items]
Net revenue	221.1	263.7
Softgel and Oral Technologies \| Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	190.6	242
Softgel and Oral Technologies \| Development Services
Disaggregation of Revenue [Line Items]
Net revenue	30.5	21.7
Softgel and Oral Technologies \| Clinical Supply Services
Disaggregation of Revenue [Line Items]
Net revenue	0	0
Oral and Specialty Drug Delivery
Disaggregation of Revenue [Line Items]
Net revenue	158.3	132.6
Oral and Specialty Drug Delivery \| Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	103.5	76
Oral and Specialty Drug Delivery \| Development Services
Disaggregation of Revenue [Line Items]
Net revenue	54.8	56.6
Oral and Specialty Drug Delivery \| Clinical Supply Services
Disaggregation of Revenue [Line Items]
Net revenue	0	0
Clinical Supply Services
Disaggregation of Revenue [Line Items]
Net revenue	92.7	84.6
Clinical Supply Services \| Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	0	0
Clinical Supply Services \| Development Services
Disaggregation of Revenue [Line Items]
Net revenue	0	0
Clinical Supply Services \| Clinical Supply Services
Disaggregation of Revenue [Line Items]
Net revenue	92.7	84.6
Total Catalent before inter-segment revenue elimination
Disaggregation of Revenue [Line Items]
Net revenue	849.2	669.5
Total Catalent before inter-segment revenue elimination \| Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	384	382.4
Total Catalent before inter-segment revenue elimination \| Development Services
Disaggregation of Revenue [Line Items]
Net revenue	372.5	202.5
Total Catalent before inter-segment revenue elimination \| Clinical Supply Services
Disaggregation of Revenue [Line Items]
Net revenue	$ 92.7	$ 84.6

Revenue Recognition Disaggreg_2

Revenue Recognition Disaggregation of Revenue by Geography (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Elimination of revenue attributable to multiple locations	$ (21.4)	$ (18.6)
Net revenue	845.7	664.7
United States
Disaggregation of Revenue [Line Items]
Net revenue	516.9	362.3
Europe
Disaggregation of Revenue [Line Items]
Net revenue	281.4	210.1
International Other
Disaggregation of Revenue [Line Items]
Net revenue	$ 68.8	$ 110.9

Revenue Recognition Contractu_2

Revenue Recognition Contractual Liabilities (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020
Revenue Recognition and Deferred Revenue [Abstract]
Contract with Customer, Liability	$ 243.9	$ 218.4
Contract with Customer, Liability, Revenue Recognized	48.2
Contract with Customer, Asset, Purchase	$ 116.2	$ 61.4

Business Combinations Acquisiti

Business Combinations Acquisition Purchase Agreement (Details) - USD ($) $ in Millions	Feb. 10, 2020	Jan. 01, 2020	Jul. 31, 2019
Novavax [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred			$ 18.3
Anagni [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred		$ 55.3
Business Combination,Consideration Transferred, Net of Transitional Service Agreement		$ 52.2
MaSTherCell [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred	$ 323.3

Business Combinations Net Asset

Business Combinations Net Assets Acquired (Details) - USD ($) $ in Millions	Feb. 10, 2020	Jan. 01, 2020	Jul. 31, 2019
Novavax [Member]
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			$ 15.6
Business Acquisition, Goodwill, Expected Tax Deductible Amount			2.4
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			$ 0.3
Anagni [Member]
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		$ 34.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory		6.5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets		$ 12.2
MaSTherCell [Member]
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	$ 25.5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	51
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	7.7
Business Acquisition, Goodwill, Expected Tax Deductible Amount	$ 252.5

Goodwill - Rollforward (Detail)

Goodwill - Rollforward (Detail) $ in Millions	3 Months Ended
Goodwill - Rollforward (Detail) $ in Millions	Sep. 30, 2020USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 2,470.6
Goodwill, Other Increase (Decrease)	(0.4)
Foreign currency translation adjustments	20.2
Ending balance	2,490.4
Biologics
Goodwill [Roll Forward]
Beginning balance	1,462.2
Goodwill, Other Increase (Decrease)	(0.4)
Foreign currency translation adjustments	8.6
Ending balance	1,470.4
Softgel and Oral Technologies
Goodwill [Roll Forward]
Beginning balance	505.5
Goodwill, Other Increase (Decrease)	0
Foreign currency translation adjustments	6.1
Ending balance	511.6
Oral and Specialty Drug Delivery
Goodwill [Roll Forward]
Beginning balance	354.7
Goodwill, Other Increase (Decrease)	0
Foreign currency translation adjustments	3.1
Ending balance	357.8
Clinical Supply Services
Goodwill [Roll Forward]
Beginning balance	148.2
Goodwill, Other Increase (Decrease)	0
Foreign currency translation adjustments	2.4
Ending balance	$ 150.6

Definite Lived Long-Lived Ass_3

Definite Lived Long-Lived Assets - Other Intangible Assets Subject to Amortization (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 1,453.7	$ 1,441.7
Accumulated Amortization	(583.4)	(553)
Net Carrying Value	$ 870.3	$ 888.7
Core technology [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	19 years	19 years
Gross Carrying Value	$ 136.9	$ 134.5
Accumulated Amortization	(86.4)	(83)
Net Carrying Value	$ 50.5	$ 51.5
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	14 years	14 years
Gross Carrying Value	$ 1,027.4	$ 1,021.3
Accumulated Amortization	(268.4)	(248)
Net Carrying Value	$ 759	$ 773.3
Product Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	11 years	11 years
Gross Carrying Value	$ 273.8	$ 270.4
Accumulated Amortization	(223.1)	(217.5)
Net Carrying Value	$ 50.7	$ 52.9
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	5 years	5 years
Gross Carrying Value	$ 15.6	$ 15.5
Accumulated Amortization	(5.5)	(4.5)
Net Carrying Value	$ 10.1	$ 11

Definite Lived Long-Lived Ass_4

Definite Lived Long-Lived Assets - Amortization Expense (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Intangible Assets Disclosure [Abstract]
Amortization expense	$ 23	$ 21.5
Remainder Fiscal 2020	68.6
2021	90.7
2022	90.1
2023	89.5
2024	88.5
2025	$ 81.4

Long-Term Obligations and Oth_4

Long-Term Obligations and Other Short-Term Borrowings - Long-Term Obligations, Presented Net of Issue Discounts and Fees Paid to Lenders, and Other Short-Term Borrowings (Detail) - USD ($) $ in Millions	Sep. 30, 2020	Jun. 30, 2020
Schedule Of Debt [Line Items]
Total long-term debt	$ 3,058.7	$ 3,018
Debt, Current	73.4	72.9
Long-term obligations, less current portion	2,985.3	2,945.1
Term loan facility U.S. dollar-denominated
Schedule Of Debt [Line Items]
Total long-term debt	926.5	928.5
Deferred purchase consideration
Schedule Of Debt [Line Items]
Total long-term debt	98.2	97.5
Capital lease obligations
Schedule Of Debt [Line Items]
Total long-term debt	149.5	142.2
Other obligations
Schedule Of Debt [Line Items]
Total long-term debt	1	1.4
Carrying Value [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure	3,058.7	3,018
Fair Value, Inputs, Level 2 [Member] \| Carrying Value [Member] \| U.S. dollar-denominated 4.875% Senior Notes due 2026
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure	445.6	445.4
Fair Value, Inputs, Level 2 [Member] \| Carrying Value [Member] \| U.S Dollar-denominated 5.00% Senior Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure	493.3	493.1
Fair Value, Inputs, Level 2 [Member] \| Carrying Value [Member] \| 2.375% Senior Euro Denominated Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure	$ 944.6	$ 909.9

Long-Term Obligations and Oth_5

Long-Term Obligations and Other Short-Term Borrowings Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($) $ in Millions	Oct. 23, 2017	Sep. 30, 2020	Jun. 30, 2020
Debt Instrument [Line Items]
Total long-term debt		$ 3,058.7	$ 3,018
Payments to Acquire Businesses, Gross	$ 950
Payable Installments for Business Acquisition	50
Installment Payment for Acquisition, Year 1		50
Installment Payment for Acquisition, Year Two		50
Installment Payment for Acquisition, Year Three		50
Installment Payment for Acquisition, Year Four		$ 50
Accrued Liabilities [Member]
Debt Instrument [Line Items]
Payments to Acquire Businesses, Gross	$ 200

Long-Term Obligations and Oth_6

Long-Term Obligations and Other Short-Term Borrowings Fair Value Measurements of Financial Instruments - Carrying Amounts and Estimated Fair Value of Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2020	Jun. 30, 2020
Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	$ 3,069.8	$ 3,005.7
Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	3,058.7	3,018
U.S. dollar-denominated 4.875% Senior Notes due 2026 \| Fair Value, Inputs, Level 2 [Member] \| Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	463.4	463.6
U.S. dollar-denominated 4.875% Senior Notes due 2026 \| Fair Value, Inputs, Level 2 [Member] \| Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	445.6	445.4
U.S Dollar-denominated 5.00% Senior Notes [Member] \| Fair Value, Inputs, Level 2 [Member] \| Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	533.7	537.9
U.S Dollar-denominated 5.00% Senior Notes [Member] \| Fair Value, Inputs, Level 2 [Member] \| Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	493.3	493.1
2.375% Senior Euro Denominated Notes [Member] \| Fair Value, Inputs, Level 2 [Member] \| Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	894.9	844.1
2.375% Senior Euro Denominated Notes [Member] \| Fair Value, Inputs, Level 2 [Member] \| Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	944.6	909.9
Senior Secured Credit Facilities & Other [Member] \| Fair Value, Inputs, Level 2 [Member] \| Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	1,177.8	1,160.1
Senior Secured Credit Facilities & Other [Member] \| Fair Value, Inputs, Level 2 [Member] \| Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	$ 1,175.2	$ 1,169.6

Earnings Per Share Earnings Per

Earnings Per Share Earnings Per Share - Additional Details (Details) - $ / shares shares in Millions	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Feb. 06, 2020
Earnings Per Share [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01
If-converted Shares, Common Stock	13.1

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Net earnings/(loss)	$ 82.4	$ 0.1
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic	13.6	8.1
Net Income (Loss) Available to Common Stockholders, Basic	$ 68.8	$ (8)
Dilutive securities issuable-stock plans	2,441,035	0
Total weighted average diluted shares outstanding	166,529,038	145,663,115
Earnings Per Share, Basic	$ 0.42	$ (0.05)
Earnings Per Share, Diluted	$ 0.41	$ (0.05)
Weighted Average Number of Shares Outstanding, Basic		145,663,115

Other Income and Expense (Detai

Other Income and Expense (Details) - USD ($) $ in Millions		3 Months Ended
Other Income and Expense (Details) - USD ($) $ in Millions		Sep. 30, 2020	Sep. 30, 2019
Other Income and Expenses [Abstract]
Debt refinancing costs		—	0.1
Foreign Currency (gains) and losses	[1]	$ (0.6)	$ (3.1)
Other	[2]	(10.6)	7.9
Other (income)/expense, net		(11.2)	4.9
Derivative, Gain (Loss) on Derivative, Net		$ 9	$ (8.9)

[1]	Foreign currency remeasurement gains include both cash and non-cash transactions.
[2]	Included within Other for the three months ended September 30, 2020 and 2019 is an unrealized gain of $9.0 million and an unrealized loss of $8.9 million, respectively, each related to the fair value of the derivative liability associated with the Series A Preferred Stock

Restructuring and Other Costs (

Restructuring and Other Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
Restructuring and other	$ 0.9	$ 0.7

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions	May 17, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Derivative [Line Items]
Total long-term debt		$ 3,058.7		$ 3,018
Unrealized foreign exchange gain/(loss) within other comprehensive income		(32.4)	$ 20.3
Unrealized foreign exchange gain/(loss) within statement of operations		(1.9)	9.7
Net accumulated gain related to investment hedges		30.1
Proceeds from Issuance of Redeemable Preferred Stock	$ 646.3
Payments of Stock Issuance Costs	3.7
Derivative Liability				23.6
Derivative, Gain (Loss) on Derivative, Net		9	$ (8.9)
Embedded Derivative, Fair Value of Embedded Derivative Liability		14.6
Embedded Derivative, Estimate of Embedded Derivative Liability	$ 39.7	3.8		$ 3.7
Euro Denominated Debt Outstanding [Member]
Derivative [Line Items]
Total long-term debt		944.6
U.S. Denominated Term Loan [Member]
Derivative [Line Items]
Total Debt, U.S Denominated Term Loan		$ 500
Debt Instrument, Interest Rate, Effective Percentage		1.26%
Total Fixed Rate		3.51%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued	$ 4.5		$ 5.6
Unrecognized tax benefits that impact the effective income tax rate	3.2		$ 4.4
Income tax expense(benefit)	(15)	$ (6.9)
Earnings from continuing operations, before income taxes	67.4	$ (6.8)
Tax Benefit, U.S foreign tax credit	$ 22.2

Employee Retirement Benefit P_3

Employee Retirement Benefit Plans - Components of Company's Net Periodic Benefit Costs (Detail) - USD ($) $ in Millions		3 Months Ended
		Sep. 30, 2020	Sep. 30, 2019
Components of net periodic benefit cost:
Service cost		$ 1	$ 0.6
Interest cost		1	1.7
Expected return on plan assets		(2.4)	(2.7)
Amortization	[1]	0.7	0.8
Net amount recognized		0.3	0.4
Estimated discounted value of future employer contributions		38.6	38.6
Estimated annual cash contribution		$ 1.7	$ 1.7

[1]	Amount represents the amortization of unrecognized actuarial gains/(losses)

Equity and Accumulated Other _3

Equity and Accumulated Other Comprehensive Income (Loss) - Equity (Details) $ / shares in Units, number in Millions, $ in Millions	Jun. 15, 2020USD ($)$ / sharesshares	Feb. 06, 2020USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2020$ / sharesshares	May 17, 2019shares
Equity [Abstract]
Common Stock, Shares Authorized			1,000,000,000	1,000,000,000
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.01	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized			100,000,000	100,000,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares			$ 0.01	$ 0.01
Equity offering, sale of common stock	7,700,000	8,400,000
Shares Issued, Price Per Share \| $ / shares	$ 70.72	$ 58.58
Equity offering, sale of common stock, net \| $	$ 547.5	$ 494.2	$ 81.8
Net Proceeds used to Repay Debt, Stock Issued During Period, New Issues \| $	$ 200	$ 100
Stcok Issued During Period, Shares, Over-allotment Option	1.2
Stock Issued During Period, Value, Over-allotment Option \| $	$ 81.8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares			200,000
Preferred Stock, Shares Issued			650,000	650,000	650,000

Equity and Accumulated Other _4

Equity and Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Foreign currency translation adjustments:
Net investment hedge	$ (32.4)	$ 20.3
Long-term intercompany loans	6.3	(6.5)
Translation adjustments	35.4	(32.3)
Total foreign currency translation adjustment, pretax	9.3	(18.5)
Tax expense/(benefit)	(6.6)	3.3
Total foreign currency translation adjustment, net of tax	15.9	(21.8)
Net change in derivatives and hedges
Net loss recognized during the period	(0.1)	0
Total derivatives and hedges, pretax	(0.1)	0
Tax expense/(benefit)	0	0
Net change in derivatives and hedges, net of tax	(0.1)	0
Net change in minimum pension liability
Net gain/(loss) recognized during the period	0.7	(0.6)
Total pension liability, pretax	0.7	(0.6)
Tax expense/(benefit)	0.2	(0.3)
Net change in minimum pension liability, net of tax	$ 0.5	$ (0.3)

Equity and Accumulated Other _5

Equity and Accumulated Other Comprehensive Income (Loss) - Rollforward (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	$ (386.3)
Other comprehensive income/(loss) before reclassifications	15.8
Amounts reclassified from accumulated other comprehensive income/(loss)	0.5
Total foreign currency translation adjustment, net of tax	15.9	$ (21.8)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	0.5	(0.3)
Net change in derivatives and hedges, net of tax	(0.1)	0
Other comprehensive income/(loss), net of tax	16.3	$ (22.1)
Ending Balance	(370)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(335.1)
Other comprehensive income/(loss) before reclassifications	15.9
Amounts reclassified from accumulated other comprehensive income/(loss)	0
Total foreign currency translation adjustment, net of tax	15.9
Ending Balance	(319.2)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(47.5)
Other comprehensive income/(loss) before reclassifications	0
Amounts reclassified from accumulated other comprehensive income/(loss)	0.5
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	0.5
Ending Balance	(47)
AOCI, Derivative Qualifying as Hedge, Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(2.6)
Other comprehensive income/(loss) before reclassifications	(0.1)
Amounts reclassified from accumulated other comprehensive income/(loss)	0
Net change in derivatives and hedges, net of tax	(0.1)
Ending Balance	(2.7)
Available-for-sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(1.1)
Other comprehensive income/(loss) before reclassifications	0
Amounts reclassified from accumulated other comprehensive income/(loss)	0
Available for sale investments	0
Ending Balance	$ (1.1)

Equity (Details)

Equity (Details) - USD ($)	May 17, 2019	Sep. 30, 2020	Jun. 30, 2020
Redeemable Preferred Stock [Line Items]
Preferred Stock, Shares Authorized		100,000,000	100,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.01	$ 0.01
Preferred Stock, Shares Issued	650,000	650,000	650,000
Preferred Stock, Value, Issued	$ 1,000
Preferred Stock, Issuance Value	650,000,000
Payments of Stock Issuance Costs	3,700,000
Preferred stock issuance Value, Net	646,300,000
Embedded Derivative, Estimate of Embedded Derivative Liability	39,700,000	$ 3,800,000	$ 3,700,000
Proceeds from Issuance of Preferred Stock and Preference Stock	606,600,000
Redeemable Preferred Stock [Member]
Redeemable Preferred Stock [Line Items]
Payments of Stock Issuance Costs	$ 3,700,000
Designated shares [Member]
Redeemable Preferred Stock [Line Items]
Preferred Stock, Shares Authorized		1,000,000

Segment Information - Net Reven

Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended
		Sep. 30, 2020	Sep. 30, 2019
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		$ 845.7	$ 664.7
Inter-segment revenue elimination		(3.5)	(4.8)
Segment Reporting Information Unallocated Expense	[1]	(28.9)	(41.4)
Biologics
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		377.1	188.6
Segment EBITDA		106.5	35.8
Softgel and Oral Technologies
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		221.1	263.7
Segment EBITDA		37.8	46.4
Oral and Specialty Drug Delivery
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		158.3	132.6
Segment EBITDA		21.4	27.7
Clinical Supply Services
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		92.7	84.6
Segment EBITDA		25	21.6
Total Catalent sub-total of Segment Reporting [Member]
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Segment EBITDA		$ 190.7	$ 131.5

[1]	Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

Segment Information, EBITDA, Re

Segment Information, EBITDA, Reconciling Items (Detail) - USD ($) $ in Millions		3 Months Ended
		Sep. 30, 2020	Sep. 30, 2019
Unallocated costs [Abstract]
Impairment Charges And Gain Loss On Sale Of Assets		$ 1.8	$ (0.2)
Stock-based compensation		18.7	16.6
Restructuring And Other Special Items		4.9	11.8
Other income/(expense),net	[1]	(11.2)	4.9
Non Allocated Corporate Costs Net		14.7	8.3
Segment Reporting Information Unallocated Expense	[2]	$ 28.9	$ 41.4

[1]	Refer to Note 8, Other (income)/expense, net, for details of financing charges and foreign currency translation adjustments recorded within other income/(expense), net.
[2]	Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

Segment Information - Reconcili

Segment Information - Reconciliation of Earnings / (Loss) from Continuing Operations to Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended
		Sep. 30, 2020	Sep. 30, 2019
Segment Reporting [Abstract]
Segment Reporting Information Unallocated Expense	[1]	$ 28.9	$ 41.4
Depreciation and amortization		69.1	60.6
Interest expense, net		25.3	36.3
Income tax expense(benefit)		(15)	(6.9)
Earnings/(loss) from continuing operations		$ 82.4	$ 0.1

[1]	Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

Segment Information - Total Ass

Segment Information - Total Assets for Each Segment and Reconciling in Consolidated Financial Statements (Detail) - USD ($) $ in Millions	Sep. 30, 2020	Jun. 30, 2020
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 7,984.2	$ 7,776.5
Biologics
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	3,995.1	3,775
Softgel and Oral Technologies
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	1,527.8	1,501.8
Oral and Specialty Drug Delivery
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	1,228.3	1,247.4
Clinical Supply Services
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	460.6	451.2
Corporate and Eliminations [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 772.4	$ 801.1

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Inventory (Detail) - USD ($) $ in Millions	Sep. 30, 2020	Jun. 30, 2020
Inventory, Net [Abstract]
Raw materials and supplies	$ 278.8	$ 222.6
Work-in-process	135	123.2
Total inventories, gross	413.8	345.8
Inventory cost adjustment	(29.5)	(22)
Inventories	$ 384.3	$ 323.8

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Prepaid and Other Assets (Detail) - USD ($) $ in Millions	Sep. 30, 2020	Jun. 30, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses	$ 49.9	$ 28.6
Contract with Customer, Asset, Net, Current	116.2	61.4
Spare parts supplies	22.4	23.1
Prepaid income tax	18.1	15
Non-U.S. value added tax	23.5	19
Other current assets	33.8	30.8
Prepaid expenses and other	$ 263.9	$ 177.9

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Property and Equipment (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Property, Plant and Equipment, Net [Abstract]
Land Buildings And Improvements	$ 1,277.1		$ 1,250.9
Machinery, equipment, and capitalized software	1,290.6		1,233.6
Furniture and fixtures	22.6		20.9
Construction in progress	546.4		440
Property, plant, and equipment, at cost	3,136.7		2,945.4
Accumulated depreciation	(1,101.2)		(1,044.6)
Property, plant, and equipment, net	2,035.5		$ 1,900.8
Depreciation Expense	$ 46.1	$ 39.1

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information - Other Accrued Liabilities (Detail) - USD ($) $ in Millions	Sep. 30, 2020	Jun. 30, 2020
Balance Sheet Related Disclosures [Abstract]
Accrued employee-related expenses	$ 140.3	$ 140.8
Restructuring accrual	2.4	2.8
Accrued interest	12.2	29.1
Contract liability	229.4	191
Accrued income tax	0	4.5
Other accrued liabilities and expenses	132.6	131.1
Other accrued liabilities	$ 516.9	$ 499.3

Subsequent Events, Business Com

Subsequent Events, Business Combination (Details) € in Millions	Oct. 28, 2020EUR (€)
Skeletal Cell Therapy Support SA \| Subsequent Event [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Price	€ 12